NPM1 and lymphoma: The experimental studies targeted nucleophosmin-1 (NPM1)-mutated acute myeloid leukaemia, multiple myeloma, certain lymphomas, lung cancers, several autoimmune diseases, graft versus host disease, certain neurological diseases, and idiopathic pulmonary fibrosis.